



SIRKULASJONSFORSTERKER

Functional feed with krill meal reduce heart pathology and viral load in heart of Atlantic salmon. Gunner Molland, Trygve Sigholt & Ralph Bickerdike PD TriNation, Dublin, June 3rd 2015

Utilising the krill effect on salmon



<u>Qardio</u>




Constituents of krill have been shown to have positive effects on the heart and circulation system in humans and warm blooded animals

Comparable and significant effects seen in other species can be transferred to farmed fish through the use of Qardio

Numerous studies have shown the beneficial effects of krill lipid fractions





part of Aker

Lipid class comparison




Qardio Phospholipids (krill oil) Triglyceride (fish oils) Structural form Choline Glycerol Phosphate Glycerol **Fatty acids** Fatty acids Charac- Non-polar Polar teristics • Hydrophobic – does NOT mix with water Hydrophilic - mixes with water Function Main structural Energy storage component in all cell membranes Fat reservoir Membrane Fat cell





Qardio

Supply all organs with blood, oxygen and nutrition



Applied comparative knowledge on benefits of krill on heart health in farmed salmon

Product development





Investigation of mode of action (PhD Uni. Aberdeen, NRC project 2015 – 2018)

Commercial trials in Norway & Scotland to confirm effects under realistic farming conditions

Controlled cardiomyopathy (PRV) challenge study to determine proof of concept & document physiological & immunological effects.

PRV transmission study, VESO 2013/2014



<u>Qardio</u>

- 4 replicates/diet, basal control or Qardio
- I00 individuals/tank, start weight 20 grams
- 8 weeks of feeding pre-transmission (cohabitant PRV)
- Sampling (heart tissue for histology & genomics):
 - 0-sampling : 6 weeks pre challenge
 - At challenge (after 6 weeks of feeding)
 - 3 6 8 9 10, 12 and 14 weeks post challenge




Growth during study



Qardio

Average weight on sampled fish




• Consistently higher growth for Qardio fed fish.

Development of heart size



<u>Qardio</u>




• Tendency for increased relative heart size for Qardio fed fish (nsd).

Gene expression in heart tissue




Qardio





(PhD. at University of Aberdeen. Supervisor: Prof Sam Martin.)




 Higher expression of genes involved in the immune defense and other cellular processes in Qardio fed fish.





<u>Qar,dio</u>



HSMI Virus load in heart

• Lower viral load in heart tissue for Qardio fed fish (p<0.05).


(qPCR analysis for PRV by Øystein Evensen (NMBU))

Sampled 8 fish per tank

Development of heart histopathology

<u>Qardio</u>

Fish with severe Ventricle damage after HSMI challenge



• Significantly lower number of fish with severe histopathology at peak time point of pathogenesis for fish fed Qardio (p<0.05).

(Histological examination by Øystein Evensen (NMBU))

BioMar

Commercial field trial 2013 - CMS



<u>Qardio</u>

- Farm located in Mid-Norway, S1-2012
- Feed trial April Sept 2013 (harvest)
- Duplicate pens fed control or Qardio

DISEASE HISTORY

- IPN post transfer to SW
- HSMI with prolonged mortality (all cages in 2012)
- CMS diagnosed in two of four trial cages in 2013




CMS signs in Cages C2 and C6



Commercial field trial 2013 - CMS

Qardio




• Lower cumulative mortality for Qardio fed fish in both cage parallels





<u>Qardio</u>




 Significant difference in histopathology score profile for Qardio fed fish. (Histological examination by Øystein Evensen (NMBU))





<u>Qardio</u>



• Tendency for increased relative heart size for Qardio fed fish (nsd.)

Commercial field trial 2014




Qardio

- Farm located in South-Norway, S1-2013.
- Feed trial May Nov 2014 (4.3kg harvest).
- Single pen fed control or Qardio.
- Site selected with historical cardiomyopathy but no disease outbreak during trial.
- 50 fish per pen assessed at harvest for heart size.

Commercial field trial 2014



<u>Qardio</u>



• Significantly larger heart size for Qardio fed fish

Consistant benefits to cardiovascular health



Qardio

| HSMI - VESO 2013 | Field trial 2013 | Field trial 2014 |
|---|--|---|
| | | |
| | | |
| Reduced viral count | | |
| | Reduced mortality | |
| Immune response | | |
| | | |
| Reduced histopathology during viral disease | | |
| | | |
| Heart development (increased relative heart size) | | |
| | | |
| | | |
| | | |
| | | |
| \wedge \wedge | \wedge \wedge | \wedge \wedge |
| $-\!$ | $ \begin{tabular}{ c c c c c } \hline \end{tabular} tabul$ | $ \begin{tabular}{ c c c c c } \hline \end{tabular} \begin{tabular}{ c c c } \hline \end{tabular} \begin{tabular}{ c c } \hline \end{tabular} $ |

Acknowledgements



<u>Qardio</u>

- Christian Wallace & colleagues (VESO)
- Øystein Evensen (NMBU)
- PhD Zeynab Heidari, Prof. Sam Martin (University of Aberdeen)
- Customers for collaboration with field trials
- AkerBioMarine

For further information contact Product Manager Gunnar Molland at Gunnar.Molland@biomar.no or your local representative